open access

Vol 5, No 5 (2009)
Review paper
Published online: 2009-12-01
Get Citation

Current options in the management of advanced renal-cell carcinoma

Piotr Wysocki, Krzysztof Krzemieniecki, Kazimierz Drosik, Piotr Potemski, Jakub Żołnierek, Maciej Krzakowski
Onkol. Prak. Klin 2009;5(5):181-188.

open access

Vol 5, No 5 (2009)
REVIEW ARTICLES
Published online: 2009-12-01

Abstract

Approximately 30% of patients with renal-cell carcinoma (RCC) have metastases at diagnosis, and 40% of patients with initially localised disease develop dissemination. There is no consensus on the optimal management of advanced RCC and complication is due - at least in part - to different outcomes of patients classified based on prognostic category. Palliative surgical interventions - nephrectomy or/and resection of metastases may play a role in many clinical situations. Advanced RCC is resistant to cytotoxic and hormonal therapy, whereas the benefit of immunotherapy (interferon α or/and interleukin 2) is modest and cytokines may be helpful for a subgroup of patients with favourable prognosis (low risk). Based on the available evidence, the use of either sunitinib or bevacizumab with interferon α could be considered in the first-line treatment for patients with favourable and intermediate prognosis (low and intermediate risk). Temsirolimus is recommended for the initial treatment of patients with unfavourable prognosis (high risk). Current evidence indicates sorafenib in cytokine refractory disease. Everolimus is an active agent in patients with progression on multikinase inhibitors (sunitinib and/or sorafenib). The following expert opinions aim to interpret and integrate the data from prospective clinical trials. Opinions presented do not apply to all patients and each should be adapted individually.

Abstract

Approximately 30% of patients with renal-cell carcinoma (RCC) have metastases at diagnosis, and 40% of patients with initially localised disease develop dissemination. There is no consensus on the optimal management of advanced RCC and complication is due - at least in part - to different outcomes of patients classified based on prognostic category. Palliative surgical interventions - nephrectomy or/and resection of metastases may play a role in many clinical situations. Advanced RCC is resistant to cytotoxic and hormonal therapy, whereas the benefit of immunotherapy (interferon α or/and interleukin 2) is modest and cytokines may be helpful for a subgroup of patients with favourable prognosis (low risk). Based on the available evidence, the use of either sunitinib or bevacizumab with interferon α could be considered in the first-line treatment for patients with favourable and intermediate prognosis (low and intermediate risk). Temsirolimus is recommended for the initial treatment of patients with unfavourable prognosis (high risk). Current evidence indicates sorafenib in cytokine refractory disease. Everolimus is an active agent in patients with progression on multikinase inhibitors (sunitinib and/or sorafenib). The following expert opinions aim to interpret and integrate the data from prospective clinical trials. Opinions presented do not apply to all patients and each should be adapted individually.
Get Citation

Keywords

renal-cell carcinoma; advanced stage; palliative treatment; immunotherapy; molecular targeted therapy

About this article
Title

Current options in the management of advanced renal-cell carcinoma

Journal

Oncology in Clinical Practice

Issue

Vol 5, No 5 (2009)

Article type

Review paper

Pages

181-188

Published online

2009-12-01

Bibliographic record

Onkol. Prak. Klin 2009;5(5):181-188.

Keywords

renal-cell carcinoma
advanced stage
palliative treatment
immunotherapy
molecular targeted therapy

Authors

Piotr Wysocki
Krzysztof Krzemieniecki
Kazimierz Drosik
Piotr Potemski
Jakub Żołnierek
Maciej Krzakowski

References (36)
  1. Wojciechowska U, Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce w 2006 roku. . Centrum Onkologii — Instytut im. Marii Skłodowskiej-Curie, Warszawa 2008.
  2. Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res. 2004; 10(18 Pt 2): 6310S–6314S.
  3. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22(3): 454–463.
  4. Escudier B, Eisen T, Stadler WM, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2): 125–134.
  5. Störkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80(5): 987–989.
  6. Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist. 2007; 12(12): 1404–1415.
  7. Brugarolas J. Renal-cell carcinoma--molecular pathways and therapies. N Engl J Med. 2007; 356(2): 185–187.
  8. Gitlitz BJ, Figlin RA. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am. 2003; 30(3): 589–600.
  9. Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003; 30(4): 843–852.
  10. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005; 23(31): 7889–7896.
  11. Hudes GR, Carducci MA, Choueiri TK, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22): 2271–2281.
  12. Rosenberg S, Yang J, White D, et al. Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Annals of Surgery. 1998; 228(3): 307–319.
  13. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000; 6 Suppl 1: S55–S57.
  14. Krown SE. Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987; 59(3 Suppl): 647–651.
  15. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. The Lancet. 1999; 353(9146): 14–17.
  16. Coppin C, Prozsolt R, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cohrane Database Sys Rev. 2005; 1: CD001425.
  17. Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. J Clin Oncol. 1999; 17(7): 2039–2043.
  18. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2): 115–124.
  19. Motzer RJ, Hutson TE, Cella D, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(22): 3584–3590.
  20. Heng DYC, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer. 2009; 115(4): 776–783.
  21. Escudier B, Pluzanska A, Koralewski P, et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370(9605): 2103–2111.
  22. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26(33): 5422–5428.
  23. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(8): 1280–1289.
  24. de Reijke TM, Bellmunt J, van Poppel H, et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009; 45(5): 765–773.
  25. Medioni J, Cojocarasu O, Belcaceres JL, et al. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2007; 18(7): 1282–1283.
  26. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4): 263–274.
  27. Shin JY, Yoon IH, Kim JS, et al. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. Cell Immunol. 2009; 256(1-2): 72–78.
  28. Wysocki PJ. Interferon + bewacyzumab — nowa generacja immunoterapii w leczeniu raka nerki? Współczesna Onkologia. 2009; 13: 74–80.
  29. Wong MKK, Jarkowski A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy. 2009; 29(4): 473–478.
  30. Bellmunt J, Négrier S, Escudier B, et al. SIOG Taskforce. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol. 2009; 69(1): 64–72.
  31. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27(20): 3312–3318.
  32. Motzer RJ, Escudier B, Oudard S, et al. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372(9637): 449–456.
  33. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009; 182(1): 29–34.
  34. Escudier B, Goupil MG, Massard C, et al. Sequential therapy in renal cell carcinoma. Cancer. 2009; 115(10 Suppl): 2321–2326.
  35. Di Lorenzo G, Cartenì G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009; 27(27): 4469–4474.
  36. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(27): 4462–4468.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl